+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Krabbe Disease Treatment Market - Global Forecast 2026-2032- Product Image
Krabbe Disease Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Krabbe Disease Treatment Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889078
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Krabbe Disease Treatment Market is projected to reach USD 2.64 Billion in 2026. It is expected to continue growing at a CAGR of 7.31%, reaching USD 4.05 Billion by 2032.

Krabbe disease is a rare, inherited lysosomal storage disorder caused by deficient galactocerebrosidase activity, leading to toxic psychosine accumulation and progressive damage to the nervous system. Treatment decisions are highly time-sensitive because outcomes are generally better when presymptomatic or very early disease is identified. Current care combines diagnostic confirmation, hematopoietic stem-cell transplantation for selected early-onset patients, and multidisciplinary supportive management. The treatment landscape is shaped by newborn-screening access, specialist capacity, genetic counseling, transplant eligibility, and the development of investigational gene-based approaches.

Early Diagnosis Is Reshaping the Treatment Landscape

The most consequential shift is the movement from symptom-led diagnosis toward earlier identification through newborn screening, molecular testing, enzyme assays, and psychosine measurement. Early detection can enable referral before irreversible neurological injury, although screening policies and follow-up pathways differ substantially by jurisdiction. Care is also becoming more coordinated, linking metabolic specialists, neurologists, transplant teams, rehabilitation professionals, nutrition services, palliative-care providers, and genetic counselors. Regulatory attention to rare pediatric diseases is supporting development of advanced therapies, while evidence generation remains difficult because the disease is uncommon, heterogeneous, and clinically progressive.

Artificial Intelligence Supports Diagnosis, Monitoring, and Research

Artificial intelligence may improve Krabbe disease care by assisting interpretation of genomic and biochemical data, identifying patterns in longitudinal neurological assessments, and helping prioritize infants for confirmatory testing. Machine-learning tools could also support trial recruitment, natural-history analysis, imaging review, and individualized monitoring. However, evidence remains limited, and AI should complement rather than replace specialist judgment. Key requirements include representative training data, external validation, explainability, privacy safeguards, and careful management of false positives in newborn-screening and diagnostic workflows.

Regional Insights: Uneven Access Defines Treatment Pathways

North America has comparatively developed rare-disease networks, transplant expertise, and newborn-screening infrastructure, but access and reimbursement vary by jurisdiction. Europe benefits from specialist metabolic centers and cross-border research collaboration, while national screening adoption and treatment pathways remain uneven. Asia-Pacific includes advanced healthcare systems with growing diagnostic capability alongside settings where specialist access is limited. Latin America continues to face challenges involving delayed diagnosis, genetic testing availability, and referral concentration. In the Middle East, investment in genomic medicine and specialized care is expanding, although coverage differs among countries. Africa faces substantial gaps in screening, confirmatory testing, transplant access, and longitudinal supportive care, making partnerships and laboratory strengthening important priorities.

Group Insights: Policy Alignment and Health-System Capacity Matter

Within ASEAN, differences in newborn screening, laboratory infrastructure, and specialist availability create varied treatment pathways. BRICS countries span substantial contrasts in population scale, diagnostic capacity, public coverage, and access to transplantation or clinical research. The European Union supports collaboration through shared research and rare-disease frameworks, but implementation remains nationally organized. G7 health systems generally possess stronger specialist and research infrastructure, while still confronting affordability and equitable access issues. GCC countries are strengthening genomic and specialized-care capabilities, with referral systems and cross-border coordination remaining relevant. NATO members represent diverse health systems, so alliance membership does not imply uniform screening or treatment access.

Country Insights: National Systems Shape Diagnosis and Care

Australia has established rare-disease and transplant expertise, although geography can complicate access. Brazil and Mexico continue to navigate regional disparities in diagnosis, genetic testing, and specialist referral. Canada and the United States have advanced centers and research capabilities, with access influenced by provincial, federal, and payer structures. China, India, and Russia are expanding rare-disease capacity but face significant geographic and infrastructure variation. Japan, South Korea, France, Germany, Italy, Spain, and the United Kingdom benefit from sophisticated specialist services, yet screening policies, reimbursement arrangements, and referral pathways differ. Across all listed countries, earlier diagnosis, coordinated follow-up, and equitable access to supportive services remain central priorities.

Action Priorities for Leaders in Krabbe Disease Care

Industry and health-system leaders should prioritize validated newborn-screening pathways linked to rapid confirmatory testing and specialist referral. They should strengthen shared diagnostic standards, psychosine and enzyme-testing capacity, genetic counseling, and registries that capture outcomes over time. Treatment programs should use multidisciplinary protocols covering transplantation, neurological care, rehabilitation, nutrition, respiratory support, and family services. Developers should design studies around presymptomatic and early disease, transparent natural-history comparators, clinically meaningful endpoints, and long-term safety monitoring. Responsible AI adoption should begin with narrowly defined, clinically supervised applications and rigorous validation. Policymakers can improve access through referral networks, cross-border expertise, and coverage mechanisms suited to rare pediatric conditions.

Research Methodology for This Executive Summary

This summary uses the supplied market definition-Krabbe disease treatment-and synthesizes established clinical, diagnostic, health-system, and policy knowledge relevant to the condition. It emphasizes verified characteristics of disease biology, recognized treatment approaches, diagnostic practices, regional health-system differences, and the role of emerging technologies. Because no underlying dataset or quantified source set was supplied, the summary intentionally excludes market estimates, market sizing, market shares, forecasts, company-specific claims, and unsupported numerical comparisons. Regional, group, and country observations are presented as qualitative context rather than as ranked assessments.

Conclusion: Earlier Identification and Coordinated Care Are Essential

Krabbe disease treatment is defined by the narrow window in which early intervention may preserve neurological function, making screening, rapid confirmation, and specialist referral central to outcomes. Hematopoietic stem-cell transplantation remains an important option for selected patients, while supportive care is essential across disease stages and investigational gene-based strategies continue to require rigorous evaluation. Progress will depend less on a single intervention than on integrated diagnostic networks, equitable access, robust long-term evidence, and responsible use of data and artificial intelligence across diverse health systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Krabbe Disease Treatment Market, by Therapy Type
7.1. Introduction
7.2. Enzyme Replacement Therapy
7.3. Gene Therapy
7.3.1. AAV Vector
7.3.2. Lentiviral Vector
7.4. Hematopoietic Stem Cell Transplantation
7.4.1. Allogeneic
7.4.2. Autologous
7.5. Supportive Therapy
8. Krabbe Disease Treatment Market, by Administration Route
8.1. Introduction
8.2. Intrathecal
8.2.1. Intracerebroventricular
8.2.2. Lumbar Puncture
8.3. Intravenous
8.3.1. Central Venous Catheter
8.3.2. Peripheral Vein
9. Krabbe Disease Treatment Market, by Patient Age Group
9.1. Introduction
9.2. Infantile
9.3. Late Onset
9.3.1. Adolescent
9.3.2. Adult
9.4. Neonatal
10. Krabbe Disease Treatment Market, by Treatment Setting
10.1. Introduction
10.2. Inpatient
10.2.1. Specialty Clinics
10.2.2. Tertiary Hospitals
10.3. Outpatient
10.3.1. Ambulatory Clinics
10.3.2. Home Care
11. Krabbe Disease Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Krabbe Disease Treatment Market, by End User
12.1. Introduction
12.2. Clinics
12.2.1. Multispecialty Clinics
12.2.2. Specialty Clinics
12.3. Home Care Providers
12.3.1. Licensed Nursing Agencies
12.3.2. Patient's Home
12.4. Hospitals
12.4.1. Children's Hospitals
12.4.2. General Hospitals
13. Krabbe Disease Treatment Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Latin America
13.6. Africa
13.7. Middle East
14. Krabbe Disease Treatment Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. BRICS
14.5. European Union
14.6. ASEAN
14.7. GCC
15. Krabbe Disease Treatment Market, by Country
15.1. Introduction
15.2. China
15.3. United States
15.4. Japan
15.5. India
15.6. Germany
15.7. United Kingdom
15.8. Australia
15.9. France
15.10. South Korea
15.11. Italy
15.12. Canada
15.13. Russia
15.14. Brazil
15.15. Mexico
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Acorda Therapeutics Inc.
17.3. Apteeus SAS
17.4. Centogene N.V.
17.5. Forge Biologics, Inc.
17.6. Gain Therapeutics, Inc.
17.7. GlaxoSmithKline Plc
17.8. Johnson & Johnson
17.9. M6P Therapeutics
17.10. Neurogene Inc.
17.11. Novartis AG
17.12. Pfizer Inc.
17.13. Polaryx Therapeutics, Inc
17.14. Polpharma
17.15. Sanofi S.A.
17.16. Takeda Pharmaceutical Company Limited
17.17. Teva Pharmaceutical Industries Ltd.
17.18. UCB Pharmaceuticals
18. Key Experts
List of Figures
FIGURE 1. Global Krabbe Disease Treatment Market, Years Considered for the Study
FIGURE 2. Global Krabbe Disease Treatment Market, Research Design
FIGURE 3. Global Krabbe Disease Treatment Market, Research Framework
FIGURE 4. Global Krabbe Disease Treatment Market, Data Triangulation
FIGURE 5. Global Krabbe Disease Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Krabbe Disease Treatment Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 7. Global Krabbe Disease Treatment Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Krabbe Disease Treatment Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 9. Global Krabbe Disease Treatment Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Krabbe Disease Treatment Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 11. Global Krabbe Disease Treatment Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Krabbe Disease Treatment Market Size, by Treatment Setting, 2025 vs 2032 (%)
FIGURE 13. Global Krabbe Disease Treatment Market Size, by Treatment Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Krabbe Disease Treatment Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Krabbe Disease Treatment Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Krabbe Disease Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Krabbe Disease Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Krabbe Disease Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Krabbe Disease Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Krabbe Disease Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Krabbe Disease Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Krabbe Disease Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Krabbe Disease Treatment Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Krabbe Disease Treatment Market Segmentation & Coverage
TABLE 2. Global Krabbe Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 4. Global Enzyme Replacement Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Enzyme Replacement Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Enzyme Replacement Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global AAV Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global AAV Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global AAV Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Lentiviral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Lentiviral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Lentiviral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Hematopoietic Stem Cell Transplantation Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Hematopoietic Stem Cell Transplantation Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Hematopoietic Stem Cell Transplantation Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Allogeneic Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Allogeneic Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Allogeneic Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Autologous Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Autologous Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Autologous Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Supportive Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Supportive Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Supportive Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 29. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Intracerebroventricular Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Intracerebroventricular Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Intracerebroventricular Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Lumbar Puncture Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Lumbar Puncture Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Lumbar Puncture Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Central Venous Catheter Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Central Venous Catheter Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Central Venous Catheter Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Peripheral Vein Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Peripheral Vein Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Peripheral Vein Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 48. Global Infantile Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Infantile Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Infantile Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Late Onset Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Late Onset Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Late Onset Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Adolescent Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Adolescent Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Adolescent Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Neonatal Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Neonatal Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Neonatal Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 64. Global Inpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Inpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Inpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Tertiary Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Tertiary Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Tertiary Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Outpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Outpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Outpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Ambulatory Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Ambulatory Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Ambulatory Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Multispecialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Multispecialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Multispecialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Home Care Providers Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Home Care Providers Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Home Care Providers Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Licensed Nursing Agencies Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Licensed Nursing Agencies Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Licensed Nursing Agencies Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Patient's Home Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Patient's Home Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Patient's Home Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Children's Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Children's Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Children's Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global General Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global General Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global General Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Krabbe Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Krabbe Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 135. Europe Krabbe Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Europe Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 137. Europe Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 138. Europe Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 139. Europe Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 140. Europe Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 141. Europe Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 142. Europe Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 143. Europe Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 144. Europe Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 145. Europe Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 146. Europe Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 147. Europe Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. Europe Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. Europe Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 150. Europe Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 151. Europe Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 152. North America Krabbe Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. North America Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 154. North America Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 155. North America Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 156. North America Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 157. North America Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 158. North America Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 159. North America Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 160. North America Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 161. North America Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 162. North America Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 163. North America Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 164. North America Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. North America Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. North America Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 167. North America Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 168. North America Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 169. Latin America Krabbe Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Latin America Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 171. Latin America Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 172. Latin America Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 173. Latin America Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 174. Latin America Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 175. Latin America Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 176. Latin America Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 177. Latin America Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 178. Latin America Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 179. Latin America Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 180. Latin America Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 181. Latin America Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 182. Latin America Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. Latin America Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 184. Latin America Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 185. Latin America Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 186. Africa Krabbe Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 187. Africa Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 188. Africa Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 189. Africa Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 190. Africa Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 191. Africa Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 192. Africa Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 193. Africa Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 194. Africa Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 195. Africa Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 196. Africa Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 197. Africa Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 198. Africa Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. Africa Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Africa Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 201. Africa Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 202. Africa Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 203. Middle East Krabbe Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 204. Middle East Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 205. Middle East Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 206. Middle East Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 207. Middle East Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 208. Middle East Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 209. Middle East Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 210. Middle East Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. Middle East Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 212. Middle East Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 213. Middle East Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 214. Middle East Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 215. Middle East Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Middle East Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Middle East Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 218. Middle East Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 219. Middle East Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 220. Global Krabbe Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. NATO Krabbe Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. NATO Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 223. NATO Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 224. NATO Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 225. NATO Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 226. NATO Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 227. NATO Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 228. NATO Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 229. NATO Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 230. NATO Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 231. NATO Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 232. NATO Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 233. NATO Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. NATO Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. NATO Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 236. NATO Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 237. NATO Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 238. G7 Krabbe Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 239. G7 Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 240. G7 Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 241. G7 Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 242. G7 Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 243. G7 Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 244. G7 Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 245. G7 Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. G7 Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 247. G7 Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 248. G7 Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 249. G7 Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 250. G7 Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 251. G7 Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. G7 Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 253. G7 Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 254. G7 Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 255. BRICS Krabbe Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 256. BRICS Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 257. BRICS Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 258. BRICS Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 259. BRICS Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 260. BRICS Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 261. BRICS Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 262. BRICS Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 263. BRICS Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 264. BRICS Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 265. BRICS Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 266. BRICS Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 267. BRICS Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. BRICS Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. BRICS Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 270. BRICS Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 271. BRICS Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 272. European Union Krabbe Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 273. European Union Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 274. European Union Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 275. European Union Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 276. European Union Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 277. European Union Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 278. European Union Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 279. European Union Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 280. European Union Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 281. European Union Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 282. European Union Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 283. European Union Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 284. European Union Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 285. European Union Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. European Union Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 287. European Union Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 288. European Union Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 289. ASEAN Krabbe Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 290. ASEAN Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 291. ASEAN Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 292. ASEAN Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 293. ASEAN Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 294. ASEAN Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 295. ASEAN Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 296. ASEAN Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 297. ASEAN Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 298. ASEAN Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 299. ASEAN Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 300. ASEAN Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 301. ASEAN Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. ASEAN Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 303. ASEAN Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 304. ASEAN Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 305. ASEAN Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 306. GCC Krabbe Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 307. GCC Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 308. GCC Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 309. GCC Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 310. GCC Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 311. GCC Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 312. GCC Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 313. GCC Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 314. GCC Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 315. GCC Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 316. GCC Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 317. GCC Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 318. GCC Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 319. GCC Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 320. GCC Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 321. GCC Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 322. GCC Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 323. Global Krabbe Disease Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 324. China Krabbe Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 325. China Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 326. China Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 327. China Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 328. China Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 329. China Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 330. China Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 331. China Krabbe Disease Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 332. China Krabbe Disease Treatment Market Size, by Late Onset, 2017-2032 (USD Million)
TABLE 333. China Krabbe Disease Treatment Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 334. China Krabbe Disease Treatment Market Size, by Inpatient, 2017-2032 (USD Million)
TABLE 335. China Krabbe Disease Treatment Market Size, by Outpatient, 2017-2032 (USD Million)
TABLE 336. China Krabbe Disease Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 337. China Krabbe Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 338. China Krabbe Disease Treatment Market Size, by Clinics, 2017-2032 (USD Million)
TABLE 339. China Krabbe Disease Treatment Market Size, by Home Care Providers, 2017-2032 (USD Million)
TABLE 340. China Krabbe Disease Treatment Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 341. United States Krabbe Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 342. United States Krabbe Disease Treatment Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 343. United States Krabbe Disease Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 344. United States Krabbe Disease Treatment Market Size, by Hematopoietic Stem Cell Transplantation, 2017-2032 (USD Million)
TABLE 345. United States Krabbe Disease Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 346. United States Krabbe Disease Treatment Market Size, by Intrathecal, 2017-2032 (USD Million)
TABLE 347. United States Krabbe Disease Treatment Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 348. United States Krabbe Disease Treatment Market Size, by Patient Age

Companies Mentioned

  • Abbott Laboratories
  • Acorda Therapeutics Inc.
  • Apteeus SAS
  • Centogene N.V.
  • Forge Biologics, Inc.
  • Gain Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • M6P Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Pfizer Inc.
  • Polaryx Therapeutics, Inc
  • Polpharma
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages196
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.64 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.05 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Krabbe Disease Treatment Market Report 2026 - Product Image

Krabbe Disease Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Krabbe Disease Treatment - Global Strategic Business Report - Product Image

Krabbe Disease Treatment - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Sphingolipidoses Treatment Market - Global Forecast 2026-2032 - Product Image

Sphingolipidoses Treatment Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Krabbe Disease Epidemiology Forecast 2025-2034 - Product Image

Krabbe Disease Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Lysosomal Disease Treatment Market Report 2026 - Product Image

Lysosomal Disease Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Krabbe Disease Drug Market

Krabbe Disease is a rare, inherited disorder of the central nervous system caused by a deficiency of the enzyme galactocerebrosidase. This deficiency leads to the accumulation of toxic substances in the brain and spinal cord, resulting in progressive neurological damage. Treatment for Krabbe Disease is limited to supportive care and enzyme replacement therapy. The Krabbe Disease Drug market is a small but growing segment of the Central Nervous System Drugs market. Currently, there are only a few drugs approved for the treatment of Krabbe Disease, and most of these are enzyme replacement therapies. These drugs are typically administered intravenously and are used to replace the missing enzyme in the body. The Krabbe Disease Drug market is expected to grow in the coming years as more drugs are developed and approved for the treatment of this rare disorder. Companies such as Genzyme Corporation, Shire Pharmaceuticals, and Sanofi-Aventis are actively involved in the development of new drugs for the treatment of Krabbe Disease. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.